Advances in NHS treatment have significantly improved outcomes for babies born with spinal muscular atrophy (SMA), a rare muscle-wasting disease. New data reveals that nearly 73% of children with the most common form of SMA now survive past two years, compared to an 8% survival rate before available treatments. The introduction of three transformative SMA medicines on the NHS since 2019, including gene therapy and oral treatment, has contributed to this positive trend. The data also suggests promising results in improving children’s quality of life. The NHS aims to continue prioritising these treatments to enhance the independence and quality of life for individuals with SMA.
4 Likes